Deciphera Pharmaceuticals, Inc. to Announce Third Quarter 2022 Financial Results and Host Conference Call and Webcast on November 3, 2022

Rhea-AI Summary

Deciphera Pharmaceuticals (NASDAQ: DCPH) announced it will report its third quarter 2022 financial results on November 3, 2022, at 8:00 AM ET. A live conference call will follow, providing insights into the financial results and corporate updates. The earnings announcement is anticipated to shed light on Deciphera's performance, especially regarding its innovative cancer therapies using their proprietary switch-control kinase inhibitor platform. QINLOCK®, their treatment for fourth-line GIST, is already approved in multiple regions, including the US and EU.

Positive

• QINLOCK® is approved in major markets including the US and EU, indicating strong market presence.
• Upcoming earnings call on November 3, 2022, may highlight significant advancements in their product pipeline.

Negative

• None.

WALTHAM, Mass.--(BUSINESS WIRE)-- Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that it will report its third quarter 2022 financial results on Thursday, November 3, 2022.

In connection with the earnings release, Deciphera’s management team will host a live conference call and webcast at 8:00 AM ET on Thursday, November 3, 2022, to discuss the Company’s financial results and provide a corporate update.

The conference call may be accessed via this link: https://register.vevent.com/register/BIddf165cd801a473885dd3605fd55f7da.

A live webcast of the conference call will be available in the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investors.deciphera.com/events-presentations. A replay will be available on the Company’s website approximately two hours after the conference call and will be available for 30 days following the call.

About Deciphera Pharmaceuticals

Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from our platform in clinical studies, QINLOCK® is Deciphera’s switch control inhibitor for the treatment of fourth-line GIST. QINLOCK is approved in Australia, Canada, China, the European Union, Hong Kong, Switzerland, Taiwan, the United Kingdom, and the United States. For more information, visit www.deciphera.com and follow us on LinkedIn and Twitter (@Deciphera).

View source version on businesswire.com: https://www.businesswire.com/news/home/20221027005155/en/

Investor Relations:

Maghan Meyers

Argot Partners

Deciphera@argotpartners.com

212-600-1902



Media:

David Rosen

Argot Partners

david.rosen@argotpartners.com

212-600-1902

Source: Deciphera Pharmaceuticals, Inc.

FAQ

When will Deciphera Pharmaceuticals report its Q3 2022 earnings?

Deciphera Pharmaceuticals will report its third quarter 2022 earnings on November 3, 2022.

What time is the earnings call for DCPH scheduled?

The earnings call for Deciphera Pharmaceuticals (DCPH) is scheduled for 8:00 AM ET on November 3, 2022.

What product is Deciphera Pharmaceuticals known for?

Deciphera Pharmaceuticals is known for QINLOCK®, a treatment for fourth-line GIST.

Where is QINLOCK® approved?

QINLOCK® is approved in the US, EU, Australia, Canada, China, Hong Kong, Switzerland, Taiwan, and the United Kingdom.